In weight loss battle, Novo and Lilly face growing offensive from licensed copies
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...
FDA says knockoff versions of weight loss drug must come off the market
Specialty pharmacies and online companies were selling the off-brand copies while there was a shortage of Zepbound and Mounjaro.
MedPage Today7h
FDA Says Compounded Tirzepatide Must Exit the Market
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
MIT Technology Review11h
Drugs like Ozempic now make up 5% of prescriptions in the US
Those are the types of clues Eli Lilly’s CEO, David Ricks, says his company will pursue next year, testing whether its GLP-1 drug, tirzepatide (called Mounjaro for diabetes treatment, and Zepbound for ...
FDA says Lilly weight loss drug shortage is over after taking a second look
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...
24/7 Wall St12h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 480.21% and ...
US FDA says Lilly's weight-loss drug shortage is resolved
The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly's blockbuster weight loss ...
A millionaire tech 'biohacker' is microdosing Zepbound to stay young
Bryan Johnson, the tech entrepreneur and millionaire who became famous for infusing his son’s plasma into his blood in an ...